Denosumab’s labeling now says a patient’s risk of developing osteonecrosis of the jaw may increase with prolonged exposure…
Can Anything Contain Drug Costs in the U.S.?
(Reuters Health)—The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue. Although brand-name drugs account for only 10% of all dispensed prescriptions in the U.S., they make up 72% of drug spending,…
A Morphine Alternative with Less Overdose Risk?
(Reuters Health)—Scientists are testing an experimental drug that’s designed to have the painkilling power of morphine without some of the side effects that can lead to overdose deaths. Initial results in mice with the compound known for now as PZM21 suggest it might be less addictive than morphine and other opiate painkillers and avoid respiratory…
FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
FDA advisory committees recommend the approvals of the abuse-deterrent opioid morphine sulfate for pain and brodalumab for plaque psoriasis…
Senior Drivers Taking Opioid Painkillers Have Higher Crash Risk
(Reuters Health)—Seniors who get behind the wheel soon after starting to use narcotic pain relievers have twice the risk of getting into a serious car crash as their peers who use non-opioid painkillers, Swedish researchers say. Senior drivers who’d been using opioid painkillers regularly for several months also had higher odds of getting into accidents,…
Most Seniors Won’t Abuse Opioids After Surgery
(Reuters Health)—Seniors who receive prescriptions for opioid drugs to control pain after major surgery don’t usually end up addicted to them, research from Canada shows. One year after having major surgery, less than 1% of patients over age 66 were still taking opioids, according to a report in JAMA Surgery. Recent research has suggested the…
Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies
Cross Reactions A recent study published online in March in the Annals of the Rheumatic Diseases investigated if the infliximab biosimilar (CT-P13, infliximab-dyyb), which is marketed in Europe as Inflectra and Remsima, can be safely and effectively substituted for infliximab (Remicade).1 Infliximab and its biosimilar are manufactured via the same process. Researchers set out to…
Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
In three clinical trials, ixekizumab proved more effective than placebo or etanercept at increasing the work attendance and productivity of patients with plaque psoriasis…
Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis
(Reuters)—Mesoblast Ltd. on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with…
U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller
WASHINGTON (Reuters)—A U.S. advisory panel on Thursday recommended approval of Egalet Corp’s long-acting opioid painkiller, Arymo ER (morphine sulfate), saying it dulls pain and could deter abuse by addicts seeking a quick high. The panel recommended that the U.S. Food and Drug Administration (FDA) approve the drug and said it deters, but does not eliminate,…
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 122
- Next Page »